OncoMatch/Clinical Trials/NCT06125652
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Is NCT06125652 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies anti Tim-3/CD123 CAR-T cell therapy for acute myeloid leukemia refractory.
Treatment: anti Tim-3/CD123 CAR-T cell therapy — To evaluate the safety and efficacy of anti Tim3/CD123 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: autologous stem cell transplant
Exception: allowed if >3 months before enrollment
Auto-SCT within the 3 months before enrollment
Lab requirements
Blood counts
hemoglobin ≥60g/l
Kidney function
serum creatinine ≤1.5×uln, or ccr≥60 ml/min
Liver function
ast ≤3×uln; alt ≤3×uln; total bilirubin ≤1.5×uln
Cardiac function
lvef≥45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify